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Summary In recent years, multimorbidity in rheumatic
conditions has gained increasing attention. Rheuma-
tologist care for an aging patient population with
multiple diseases, therefore multimorbidity is the
rule, not the exception. Owing to the high prevalence
and the potential interaction of coexisting diseases,
multimorbidity needs to be taken into account when
treating patients with chronic inflammatory condi-
tions. In this review we address the most prevalent
comorbidities in patients with rheumatic conditions
and their impact on important outcomes, such as
physical function, quality of life, and mortality.
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Over the last decade, interest in the concept of comor-
bidity and multimorbidity has increased [1–3]. This is
likely due to the fact that clinicians are facing an aging
population with multiple morbid conditions occur-
ring in one individual. Especially for the rheumatol-
ogist, treating mainly chronic systemic inflammatory
diseases, multimorbidity is the rule not the exception.
The average rheumatoid arthritis (RA) patient has 1.6
additional conditions, increasing with age, disease du-
ration, and/or disease activity.
Multimorbidity is defined as the “co-existence of
two or more chronic diseases in the same individual.”
It is a holistic concept, taking into account all poten-
tial interactions of co-existing diseases and its impact
on the patient’s overall well-being [4]. For rheumatol-
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ogists, understanding the complex role of multimor-
bidity is indispensable to provide safe, efficient, and
optimal care of our patients.
Prevalence of multimorbidity in rheumatic condi-
tions
Based on the published literature, the prevalence of
multimorbidity in the general population is about
25% [1], but prevalence estimates vary widely de-
pending on the cohort’s age distribution and methods
used to assess multimorbidity. The systemic inflam-
matory pathophysiological component of rheumatic
conditions is inevitably accompanied by multiple
other conditions in one individual and, therefore,
multimorbid patients are highly prevalent in rheuma-
tology [5]. Approximately two third of patients with
RA are considered to be multimorbid. Studies have
shown that certain morbidities co-exist because of
a shared risk factor profile leading to high co-occur-
rence rates, such as smoking, obesity, or a sedentary
lifestyle. Some studies describe an association of
multimorbidity with female gender and low socioeco-
nomic status, but only a few studies have investigated
the causes and risk factors for multimorbid patients
in detail [1, 6]. Data on prevalence rates of multimor-
bidity mainly exist for RA patients, whereas for other
rheumatic conditions such as psoriatic arthritis (PsA),
systemic lupus erythematosus (SLE), or ankylosing
spondylitis (AS), only limited data are available. Also
for other chronic inflammatory conditions such as
inflammatory bowel disease (IBD), only a few studies
are available addressing the incidence and impor-
tance of multimorbidity [7]. The highest prevalence
rates of cardiovascular diseases, depression, and os-
teoporosis can be observed in RA patients [8, 9]. The
prevalence rates of the main conditions for distinct
rheumatic conditions are listed in Table 1.
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Table 1 Prevalenceof differentmorbid conditions in in-
flammatory rheumatic conditions




















Osteoporosis 30 13 23
Cancer (any solid) 5 3 3.2
Depression 15 11 46
RA rheumatoid arthritis, SLE systemic lupus erythematosus, SpA spondy-
larthropathies
Malignancies
Rheumatic patients are at increased risk of developing
certain malignancies, mainly lymphoproliferative dis-
orders in RA, SLE, or Sjoegren syndrome [10, 11]. For
other malignancies such as colorectal cancer, a de-
creased risk can be observed, possibly due to chronic
use of NSAIDs.
Over the last few years, increasing evidence was
found demonstrating there is no increased risk of
most cancers for RA patients on tumor necrosis factor
(TNF)-inhibitor therapy compared with conventional
disease-modifying anti-rheumatic drug (DMARD)
therapy such as methotrexate or leflunomide, and
that the risk of cancer did not increase over time for
patients on TNF inhibitor therapy [12]. Furthermore,
in retrospective case control studies, the risk of cancer
recurrence in RA patients treated with TNF inhibitors
was similar to that for TNF-naïve patients [13, 14].
Cardiovascular disease
Owing to the chronic inflammatory character, a shared
risk profile such as smoking or physical inactivity and
a higher risk of cardiovascular (CV) morbidity and
mortality can be observed in many rheumatic con-
ditions such as RA or PsA [15–18]. Young women
with SLE may be up to 50 times more likely to suffer
from myocardial infarction compared with popula-
tion-based controls [19]. The rate of CVD in patients
with AS is not fully clear with some studies show-
ing a higher prevalence compared with the general
population [20, 21], losing statistical significance after
adjusting for NSAID use [22]. The stringent control of
disease activity plays a central role in minimizing CV
risk as it leads to a reduction of inflammation. It has
been shown that despite disease control, DMARDs
can also improve lipid profile [23, 24] or diabetes [25],
which reduces the risk of CV outcomes. The European
League Against Rheumatism (EULAR) has acknowl-
edged the importance of CV disease in inflammatory
arthritis and has provided recommendations for CV
risk assessment and management [26].
Osteoporosis and pulmonary disease
A higher prevalence of osteoporosis can be observed
in patients with rheumatic conditions. The increased
risk is mainly induced by glucocorticoid therapy but is
also due to immobility and inflammation [27]. Espe-
cially in SLE patients, an increased incidence of osteo-
porosis and symptomatic fractures can be observed,
which is mainly related to steroid therapy, disease du-
ration, and disease severity [28]. The increased risk of
major fracture in RA patients is taken into account in
various osteoporosis risk assessment tools [29].
Recent studies demonstrated an increased preva-
lence and risk of mortality due to respiratory disease
in RA patients independent of smoking [30].
Impact of multimorbidity on important outcomes
Owing the increasing prevalence of multimorbidity,
the clinical but also health economic implications
have become more prominent, with an exponential
rise in costs with increasing number of concomitant
chronic conditions [31]. Multimorbidity can impact
therapeutic decisions as well as important clinical
outcomes.
Treatment
It is known from previous studies that multimorbid
patients with RA are potentially undertreated for their
concomitant disease [32], which might have a neg-
ative effect on RA disease activity. Furthermore, we
were able to show different treatment patterns in mul-
timorbid RA patients, with a significant lower odds of
biological DMARD use in multimorbid RA patients,
even if needed because of persisting high disease ac-
tivity. This is of special importance as it was shown
that a more intensive treatment of rheumatic condi-
tions leads to a significant improvement of co-existing
conditions, such as CV disease or metabolic syndrome
[33, 34].
Guidelines such as “treat to target” or EULAR treat-
ment recommendations were developed in order to
achieve optimal therapeutic outcomes in patients
with rheumatic conditions. Such strategies based on
systematic literature reviews and expert opinion were
developed for patients with a single rheumatic condi-
tion only and therefore might overlook multimorbid-
ity [35]. Owing to the given inclusion and exclusion
criteria, clinical trials exclude multimorbid patients,
which limits the generalizability of results and there-
fore makes it difficult to apply recommendations to
daily routine patients. Further studies are needed to
assess the effectiveness and safety of DMARD therapy
in the subgroup of multimorbid rheumatic patients.
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Fig. 1 Impact ofmultimor-
bidity ondisease-related
outcomes: a increaseof pa-
tients’ global assessment
of diseaseactivitywith ris-






It was shown that with an increasing number of co-
existing morbidities per patients, a higher activity of
the rheumatic condition could be observed. Multi-
morbid patients are less likely to achieve treatment
targets such as remission or low disease activity. We
found that even after adjusting for important covari-
ates such as age, disease duration, or number of pre-
vious DMARDs, the odds of achieving remission de-
creased by 28% per additional morbidity 1 year after
DMARD initiation [36–38]. This might be due to the
interaction of co-existing diseases, polypharmacy, or
the tendency to undertreat multimorbid patients [39].
Furthermore, measures of disease activity devel-
oped to assess treatment targets, such as the disease
activity score (DAS) or the clinical disease activity in-
dex (CDAI), comprise patient-reported outcomes such
as patient global assessment of disease activity (PGA),
which might be directly affected by multimorbidity.
In a recent study of RA patients we found an almost
linear increase of PGA with increasing number of mor-
bidities per patient, independent of RA disease activity
(Fig. 1a; [40]).
Physical function and quality of life
The burden of multimorbidity has a negative impact
on important outcomes such as health-related quality
of life (HRQoL) or physical function, independent of
disease activity. Even for RA patients in remission,
a significant increase of physical impairment with
an increasing number of concomitant diseases was
found (Fig. 1b), underlining the overall burden of
multimorbidity not only for the individual patient
but also for society because of higher rates of work
disability [41–43]. In population-based studies it was
shown that the negative impact of multimorbidity
on function and HRQol is highest in patients having
a rheumatic condition as part of their multimorbid-
ity [44].
Mortality
Over the last decade after introducing biological
DMARD therapy, an improvement in disease activity
and increasing remission rates were achieved. Never-
theless, despite optimum treatment strategies, a so-
called mortality gap can be observed, showing a de-
crease in mortality in the general population whereas
mortality rates in patients with rheumatic conditions
remain high or even show a trend of increasing over
time [45]. Radovits et al. showed that concomitant
conditions are the strongest predictor of mortality
[46]. In register studies of RA patients, cardiovascular
and respiratory mortality were increased [47, 48]; for
other rheumatic conditions, higher mortality due to
cancer was found [49].
Conclusion
In patients with chronic inflammatory rheumatic con-
ditions, multimorbidity is highly prevalent with an
impact on important clinical outcomes such as dis-
ease activity, physical function, or mortality. By un-
derstanding and implementing the concept of multi-
morbidity, quality of care and clinical outcomes can
be improved.
Open access funding provided by Medical University of Vi-
enna.
Conflict of interest H. Radner declares that she has no com-
peting interests.
Open Access This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which per-
mits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the origi-
788 Multimorbidity in rheumatic conditions K
review article
nal author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
References
1. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of
multimorbidity and implications for health care, research,
and medical education: a cross-sectional study. Lancet.
2012;380(9836):37–43.
2. Diederichs C, Berger K, Bartels DB. The measurement of
multiple chronicdiseases –a systematic reviewonexisting
multimorbidity indices. J Gerontol A Biol Sci Med Sci.
2010;66(3):301–11.
3. FortinM, StewartM, PoitrasME, et al. A systematic review
of prevalence studies on multimorbidity: toward a more
uniformmethodology. AnnFamMed. 2012;10(2):142–51.
4. Radner H, Yoshida K, Smolen JS, et al. Multimorbidity
and rheumatic conditions-enhancing the concept of
comorbidity. NatRevRheumatol. 2014;10(4):252–6.
5. Sattar N,McInnes IB. Vascular comorbidity in rheumatoid
arthritis: potential mechanisms and solutions. CurrOpin
Rheumatol. 2005;17(3):286–92.
6. Uijen AA, van de Lisdonk EH. Multimorbidity in primary
care: prevalence and trendover the last 20 years. Eur J Gen
Pract. 2008;14(Suppl1):28–32.
7. Roman AL, Munoz F. Comorbidity in inflammatory bowel
disease.WorldJGastroenterol. 2011;17(22):2723–33.
8. DougadosM,SoubrierM,AntunezA,etal. Prevalenceofco-
morbidities in rheumatoidarthritis andevaluationof their





tis. Results from34countriesparticipating in theQuest-RA
program.ClinExpRheumatol. 2014;32(6):869–77.
10. Bernatsky S, Boivin JF, Joseph L, et al. An international
cohort study of cancer in systemic lupus erythematosus.
ArthritisRheum. 2005;52(5):1481–90.
11. SmittenAL,SimonTA,HochbergMC,etal. Ameta-analysis
of the incidence of malignancy in adult patients with
rheumatoidarthritis. ArthritisResTher. 2008;10(2):R45.
12. Askling J, van Vollenhoven RF, Granath F, et al. Cancer
risk inpatientswith rheumatoidarthritis treatedwith anti-
tumornecrosis factoralphatherapies: does theriskchange
with the time since start of treatment? Arthritis Rheum.
2009;60(11):3180–9.
13. Raaschou P, Frisell T, Askling J, et al. TNF inhibitor
therapy and risk of breast cancer recurrence in patients
with rheumatoidarthritis: anationwidecohort study. Ann
RheumDis. 2015;74(12):2137–43.
14. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or
recurrent malignancies among patients with rheumatoid
arthritis exposed to biologic therapy in the German
biologicsregisterRABBIT.ArthritisResTher. 2010;12(1):R5.
15. Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular
comorbidities in patients with psoriatic arthritis: a
systematicreview. AnnRheumDis. 2013;72(2):211–6.
16. Raterman HG, Levels H, Voskuyl AE, et al. HDL pro-
tein composition alters from proatherogenic into less
atherogenic and proinflammatory in rheumatoid arthri-
tis patients responding to rituximab. Ann Rheum Dis.
2013;72(4):560–5.
17. SolomonDH, Curhan GC, RimmEB, et al. Cardiovascular
risk factors in women with and without rheumatoid
arthritis. ArthritisRheum. 2004;50(11):3444–9.
18. MurraySG,YazdanyJ,KaiserR,etal.Cardiovasculardisease
and cognitive dysfunction in systemic lupus erythemato-
sus. ArthritisCareRes(Hoboken). 2012;64(9):1328–33.
19. ManziS,MeilahnEN,Rairie JE,etal.Age-specific incidence
rates of myocardial infarction and angina in women with
systemic lupus erythematosus: comparison with the
FraminghamStudy. AmJEpidemiol. 1997;145(5):408–15.




21. Nurmohamed MT, van der Horst-Bruinsma I, Maksy-
mowychWP.Cardiovascular and cerebrovascular diseases
inankylosingspondylitis: currentinsights. CurrRheumatol
Rep. 2012;14(5):415–21.
22. Essers I, StolwijkC,BoonenA, et al. Ankylosing spondylitis
and risk of ischaemic heart disease: a population-based
cohortstudy. AnnRheumDis. 2016;75(1):203–9.
23. MorrisSJ,WaskoMC,AntoheJL,etal. Hydroxychloroquine
use associated with improvement in lipid profiles in
rheumatoidarthritispatients. ArthritisCareRes(Hoboken).
2011;63(4):530–4.
24. Jamnitski A, Visman IM, Peters MJ, et al. Beneficial effect
of 1-year etanercept treatment on the lipid profile in
responding patients with rheumatoid arthritis: the ETRA
study. AnnRheumDis. 2010;69(11):1929–33.
25. Solomon DH, Massarotti E, Garg R, et al. Association
between disease-modifying antirheumatic drugs and
diabetes risk in patients with rheumatoid arthritis and
psoriasis. JAMA.2011;305(24):2525–31.
26. Peters MJ, Symmons DP, McCarey D, et al. EULAR
evidence-based recommendations for cardiovascular risk
management in patients with rheumatoid arthritis and





28. Bultink IE, Lems WF. Lupus and fractures. Curr Opin
Rheumatol. 2016;28(4):426–32.
29. Kanis JA, Oden A, Johansson H, et al. FRAX and its
applicationstoclinicalpractice. Bone. 2009;44(5):734–43.
30. Sparks JA, Chang SC, Liao KP, et al. Rheumatoid arthritis
andmortalityamongwomenduring36yearsofprospective
follow-up: results from theNurses’ Health Study. Arthritis
Care Res (Hoboken). 2015;68(6):753–62. doi:10.1002/acr.
22752.
31. Wolff JL, StarfieldB,AndersonG.Prevalence, expenditures,
and complications of multiple chronic conditions in the
elderly. ArchInternMed. 2002;162(20):2269–76.
32. Toms TE, Panoulas VF, Douglas KM, et al. Statin use
in rheumatoid arthritis in relation to actual cardiovas-
cular risk: evidence for substantial undertreatment of
lipid-associated cardiovascular risk? Ann Rheum Dis.
2010;69(4):683–8.
33. Costa L, Caso F, Atteno M, et al. Impact of 24-month
treatment with etanercept, adalimumab, ormethotrexate
onmetabolicsyndromecomponents inacohortof210pso-
riaticarthritispatients. ClinRheumatol. 2014;33(6):833–9.
34. Dixon WG, Watson KD, Lunt M, et al. Reduction in
the incidence of myocardial infarction in patients with
rheumatoid arthritis who respond to anti-tumor necrosis
factor alpha therapy: results from the British Society
for Rheumatology Biologics Register. Arthritis Rheum.
2007;56(9):2905–12.
35. BoydCM,Darer J,BoultC, etal. Clinicalpracticeguidelines
andqualityofcareforolderpatientswithmultiplecomorbid
K Multimorbidity in rheumatic conditions 789
review article
diseases: implications for pay for performance. JAMA.
2005;294(6):716–24.
36. RanganathVK,MaranianP,ElashoffDA,etal. Comorbidities
are associated with poorer outcomes in community pa-
tients with rheumatoid arthritis. Rheumatology (Oxford).
2013;52(10):1809–17.
37. RadnerH,YoshidaK,FritsM,etal. Theimpactofmultimor-
bidity status on treatment response in rheumatoid arthri-
tis patients initiating disease-modifying anti-rheumatic
drugs. Rheumatology(Oxford). 2015;54(11):2076–84.
38. Eder L, Thavaneswaran A, Chandran V, et al. Obesity is
associatedwith a lower probability of achieving sustained
minimaldiseaseactivitystateamongpatientswithpsoriatic
arthritis. AnnRheumDis. 2015;74(5):813–7.
39. Radner H, Yoshida K, Hmamouchi I, et al. Treatment
patternsofmultimorbidpatientswithrheumatoidarthritis:
results from an international cross-sectional study. J
Rheumatol. 2015;42(7):1099–104.
40. Radner H, Yoshida K, Tedeschi SK, Frits M, Iannacone C,
Shadick N, Weinblatt M, Aletaha D, Smolen JS, Solomon
DH.Differentperceptionofdiseaseactivity inMultimorbid
rheumatoid arthritis patients [abstract]. Arthritis Rheum.
2015;67(Suppl10):abstract3258.
41. Rupp I, Boshuizen HC, Jacobi CE, et al. Comorbidity in
patientswithrheumatoidarthritis: effectonhealth-related
qualityof life. JRheumatol. 2004;31(1):58–65.
42. Radner H, Smolen JS, Aletaha D. Comorbidity affects all
domains of physical functionand quality of life inpatients
with rheumatoid arthritis. Rheumatology (Oxford).
2010;50(2):381–8.
43. Radner H, Smolen JS, Aletaha D. Impact of comorbidity
onphysical function in patientswith rheumatoid arthritis.
AnnRheumDis. 2009;69(3):536–41.
44. Loza E, Jover JA, RodriguezL, et al. Multimorbidity: preva-
lence, effect on quality of life and daily functioning, and
variation of this effect when one condition is a rheumatic
disease. SeminArthritisRheum. 2009;38(4):312–9.
45. Gabriel SE, Michaud K. Epidemiological studies in in-
cidence, prevalence, mortality, and comorbidity of the
rheumaticdiseases. ArthritisResTher. 2009;11(3):229.
46. Radovits BJ, Fransen J, Al Shamma S, et al. Excess
mortality emerges after 10 years in an inception cohort of
early rheumatoid arthritis. Arthritis Care Res (Hoboken).
2010;62(3):362–70.
47. England BR, Sayles H, Michaud K, et al. Cause-specific
mortality in male US veterans with rheumatoid arthritis.
ArthritisCareRes(Hoboken). 2016;68(1):36–45.
48. Sparks JA, Chang SC, Liao KP, et al. Rheumatoid arthritis
andmortalityamongwomenduring36yearsofprospective
follow-up: results from the nurses’ health study. Arthritis
CareRes(Hoboken). 2016;68(6):753–62.
49. Mok CC, Kwok CL, Ho LY, et al. Life expectancy, stan-




prediction of osteoporosis in a contemporary cohort
of patients with rheumatoid arthritis. Rheumatology
(Oxford). 2014;53(10):1759–66.
51. Molto A, Etcheto A, van der Heijde D, et al. Prevalence
of comorbidities and evaluation of their screening in
spondyloarthritis: results of the international cross-
sectional ASAS-COMOSPA study. Ann Rheum Dis.
2016;75(6):1016–23.
52. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy
in systemic lupus erythematosus. Arthritis Rheum.
1996;39(6):1050–4.
53. AlmehedK,Forsbladd’EliaH,KvistG, etal. Prevalenceand
riskfactorsofosteoporosisinfemaleSLEpatients-extended
report. Rheumatology(Oxford). 2007;46(7):1185–90.
54. Nery FG, Borba EF, Viana VS, et al. Prevalence of
depressive and anxiety disorders in systemic lupus ery-
thematosus and their association with anti-ribosomal P
antibodies. ProgNeuropsychopharmacol Biol Psychiatry.
2008;32(3):695–700.
55. Sabio JM, Vargas-Hitos JA, Navarrete-Navarrete N, et al.
Prevalence of and factors associated with hypertension in
youngandoldwomenwithsystemic lupuserythematosus.
JRheumatol. 2011;38(6):1026–32.
56. TseliosK,KoumarasC,GladmanDD, et al. Dyslipidemia in
systemic lupus erythematosus: just another comorbidity?
SeminArthritisRheum. 2016;45(5):604–10.
790 Multimorbidity in rheumatic conditions K
